FDA clears IND application for EVOLVE104 for the treatment of solid tumors
“This IND clearance represents a transformational milestone for our company, as it paves the way for our advancement into a clinical-stage developer of next-generation trispecific T cell engagers,” said Stephen Bloch, M.D., chief executive officer of EvolveImmune. “We have long believed that the integrated CD2 costimulation strategy underpinning EVOLVE has differentiated potential to deliver best-in-class T cell engagers that offer meaningful clinical benefits to patients with cancer. We are excited to evaluate this hypothesis in a clinical setting. We expect to initiate our first-in-human clinical trial for EVOLVE104 in the coming months.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines